WO2004066960A3 - Combinaison d'antagonistes des recepteurs h1, h3 et h4 en vue du traitement d'inflammations pulmonaires allergiques et non allergiques, de congestions et de rhinites allergiques - Google Patents
Combinaison d'antagonistes des recepteurs h1, h3 et h4 en vue du traitement d'inflammations pulmonaires allergiques et non allergiques, de congestions et de rhinites allergiques Download PDFInfo
- Publication number
- WO2004066960A3 WO2004066960A3 PCT/US2004/003565 US2004003565W WO2004066960A3 WO 2004066960 A3 WO2004066960 A3 WO 2004066960A3 US 2004003565 W US2004003565 W US 2004003565W WO 2004066960 A3 WO2004066960 A3 WO 2004066960A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- allergic
- receptor antagonists
- congestion
- treatment
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des méthodes de traitement de pathologies allergiques faisant intervenir les voies aériennes par administration d'antagonistes des récepteurs de l'histamine.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44320703P | 2003-01-28 | 2003-01-28 | |
US60/443,207 | 2003-01-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004066960A2 WO2004066960A2 (fr) | 2004-08-12 |
WO2004066960A3 true WO2004066960A3 (fr) | 2004-10-21 |
Family
ID=32825306
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/003565 WO2004066960A2 (fr) | 2003-01-28 | 2004-01-26 | Combinaison d'antagonistes des recepteurs h1, h3 et h4 en vue du traitement d'inflammations pulmonaires allergiques et non allergiques, de congestions et de rhinites allergiques |
Country Status (2)
Country | Link |
---|---|
US (1) | US20050090527A1 (fr) |
WO (1) | WO2004066960A2 (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0525029D0 (en) * | 2005-12-08 | 2006-01-18 | Univ Hull | Receptor Antagonist |
WO2007120690A2 (fr) * | 2006-04-10 | 2007-10-25 | Janssen Pharmaceutica N.V. | Thérapie combinée avec des antagonistes des récepteurs histaminiques h1r et h4r pour le traitement du prurit |
US7985745B2 (en) | 2006-10-02 | 2011-07-26 | Abbott Laboratories | Method for pain treatment |
WO2008108957A2 (fr) * | 2007-03-02 | 2008-09-12 | Schering Corporation | Dérivés pipéridines et leurs procédés d'utilisation |
FR2924344B1 (fr) * | 2007-12-04 | 2010-04-16 | Pf Medicament | Utilisation de la mequitazine sous la forme de racemate ou d'enantiomeres pour la preparation d'un medicament destine au traitement ou a la prevention de pathologies impliquant les recepteurs histaminiques h4. |
EP3943069B1 (fr) | 2009-03-17 | 2024-11-27 | Nicox Ophthalmics, Inc. | Formulations ophtalmiques de cetirizine et procedes d'utilisation |
US8569273B2 (en) | 2009-03-17 | 2013-10-29 | Aciex Therapeutics, Inc. | Ophthalmic formulations of cetirizine and methods of use |
WO2012012390A1 (fr) | 2010-07-19 | 2012-01-26 | Marvphyt Development Llc | Composition botanique et procédés de fabrication et utilisation |
US9364510B2 (en) | 2011-07-19 | 2016-06-14 | Marvphyt Development Llc | Botanical composition and methods of manufacture and use |
WO2013151982A1 (fr) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Méthodes et composés utiles pour traiter le prurit, et procédés d'identification desdits composés |
EP3378476A1 (fr) | 2012-06-08 | 2018-09-26 | Sensorion | Inhibiteurs du récepteur h4 destinés au traitement des acouphènes |
BR102018073582A2 (pt) * | 2017-11-15 | 2020-07-07 | Bioprojet | Enantiômero, processo de preparação de um enantiômero, uso do enantiômero, composição farmacêutica e combinação |
WO2019149863A1 (fr) * | 2018-01-31 | 2019-08-08 | Zarodex Therapeutics Limited | Clozapine pour le traitement de maladies de lymphocytes b entraînées par ig-e |
CN119823227A (zh) * | 2025-01-14 | 2025-04-15 | 北京川晋生物科技有限公司 | 一种益生菌的制备方法及其在治疗过敏性鼻炎中的用途 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998006394A1 (fr) * | 1996-08-16 | 1998-02-19 | Schering Corporation | Traitement des reponses allergiques des voies aeriennes superieures a l'aide d'une combinaison d'antagonistes des recepteurs de l'histamine |
US5869479A (en) * | 1997-08-14 | 1999-02-09 | Schering Corporation | Treatment of upper airway allergic responses |
WO1999024406A1 (fr) * | 1997-11-07 | 1999-05-20 | Schering Corporation | Phenyl-alkyl-imidazoles utilises comme antagonistes du recepteur h¿3? |
US5990147A (en) * | 1997-11-07 | 1999-11-23 | Schering Corporation | H3 receptor ligands of the phenyl-alkyl-imidazoles type |
US6100279A (en) * | 1998-11-05 | 2000-08-08 | Schering Corporation | Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom |
WO2002024658A2 (fr) * | 2000-09-20 | 2002-03-28 | Schering Corporation | Imidazoles substituees utiles en tant qu'agonistes ou qu'antagonistes de l'histamine h1 et/ou h¿3? |
WO2002032893A2 (fr) * | 2000-10-17 | 2002-04-25 | Schering Corporation | Nouveaux composes non imidazole |
WO2002044141A2 (fr) * | 2000-09-20 | 2002-06-06 | Schering Corporation | Imidazoles substituees utilisees comme agonistes ou antagonistes doubles d'histamine h1 et h3 |
WO2002056871A2 (fr) * | 2001-01-17 | 2002-07-25 | Pfizer Limited | Antagonistes de recepteur de l'histamine |
WO2002072093A2 (fr) * | 2001-02-08 | 2002-09-19 | Schering Corporation | Utilisation d'antagonistes doubles h3 et m2 dans le traitement de troubles cognitifs |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5217986A (en) * | 1992-03-26 | 1993-06-08 | Harbor Branch Oceanographic Institution, Inc. | Anti-allergy agent |
US5352707A (en) * | 1992-03-26 | 1994-10-04 | Harbor Branch Oceanographic Institution, Inc. | Method for treating airway congestion |
US6204017B1 (en) * | 1999-10-07 | 2001-03-20 | Schering Corporation | Polynucleotide encoding a histamine receptor |
-
2004
- 2004-01-26 US US10/764,780 patent/US20050090527A1/en not_active Abandoned
- 2004-01-26 WO PCT/US2004/003565 patent/WO2004066960A2/fr active Application Filing
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998006394A1 (fr) * | 1996-08-16 | 1998-02-19 | Schering Corporation | Traitement des reponses allergiques des voies aeriennes superieures a l'aide d'une combinaison d'antagonistes des recepteurs de l'histamine |
US5869479A (en) * | 1997-08-14 | 1999-02-09 | Schering Corporation | Treatment of upper airway allergic responses |
WO1999024406A1 (fr) * | 1997-11-07 | 1999-05-20 | Schering Corporation | Phenyl-alkyl-imidazoles utilises comme antagonistes du recepteur h¿3? |
US5990147A (en) * | 1997-11-07 | 1999-11-23 | Schering Corporation | H3 receptor ligands of the phenyl-alkyl-imidazoles type |
US6100279A (en) * | 1998-11-05 | 2000-08-08 | Schering Corporation | Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom |
WO2002024658A2 (fr) * | 2000-09-20 | 2002-03-28 | Schering Corporation | Imidazoles substituees utiles en tant qu'agonistes ou qu'antagonistes de l'histamine h1 et/ou h¿3? |
WO2002044141A2 (fr) * | 2000-09-20 | 2002-06-06 | Schering Corporation | Imidazoles substituees utilisees comme agonistes ou antagonistes doubles d'histamine h1 et h3 |
WO2002032893A2 (fr) * | 2000-10-17 | 2002-04-25 | Schering Corporation | Nouveaux composes non imidazole |
WO2002056871A2 (fr) * | 2001-01-17 | 2002-07-25 | Pfizer Limited | Antagonistes de recepteur de l'histamine |
WO2002072093A2 (fr) * | 2001-02-08 | 2002-09-19 | Schering Corporation | Utilisation d'antagonistes doubles h3 et m2 dans le traitement de troubles cognitifs |
Non-Patent Citations (2)
Title |
---|
TEDFORD, CLARK E. ET AL: "Development of trans-2-[1H-imidazol-4-yl] cyclopropane derivatives as new high-affinity histamine H3 receptor ligands", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS , 289(2), 1160-1168 CODEN: JPETAB; ISSN: 0022-3565, 1999, XP002267428 * |
WOLIN, RONALD ET AL: "Novel H3 receptor antagonists. Sulfonamide homologs of histamine", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS , 8(16), 2157-2162 CODEN: BMCLE8; ISSN: 0960-894X, 1998, XP004137238 * |
Also Published As
Publication number | Publication date |
---|---|
WO2004066960A2 (fr) | 2004-08-12 |
US20050090527A1 (en) | 2005-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL376440A1 (en) | Pyridopyrrolizine and pyridoindolizine derivatives | |
DE60215000D1 (de) | DIHYDROPYRROLOi1,2-AöINDOL- UND TETRAHYDROPYRIDOi1,2-AöINDOLDERIVATE ALS PROSTAGLANDIN REZEPTOR ANTAGONISTEN | |
WO2002072570A3 (fr) | Nouveaux composes non-imidazole | |
WO2004066960A3 (fr) | Combinaison d'antagonistes des recepteurs h1, h3 et h4 en vue du traitement d'inflammations pulmonaires allergiques et non allergiques, de congestions et de rhinites allergiques | |
HK1114013A1 (en) | The combination of anticholinergics and leukotriene receptor antagonists for the treatment of repiratory diseases | |
WO2002089729A3 (fr) | Composes heterocycliques fondus | |
PL376373A1 (en) | Selected cgrp antagonists, method for production and use thereof as medicament | |
LTC1830843I2 (lt) | Indolidono dariniai, skirti fibrozinių ligų gydymui arba prevencijai | |
IL168056A0 (en) | Selected cgrp antagonists, method for production and use thereof as medicament | |
BR0314059A (pt) | Compostos heterocìclicos | |
MY132566A (en) | Benzimidazolone histamine h3 antagonists | |
WO2002032374A3 (fr) | Methodes de traitement de troubles induits par l'il-18 | |
WO2006002437A3 (fr) | Traitement d'etats pathologiques impliquant la demyelinisation | |
WO2002058685A3 (fr) | Combinaisons d'acide nicotinique et de derives de ce dernier, inhibiteur(s) d'absorption de sterols et traitements de conditions vasculaires | |
WO2004009062A3 (fr) | Antagonistes du recepteur nmda et leur utilisation pour inhiber l'hyperphosphorylation de la proteine associee aux microtubules tau | |
WO2005072308A3 (fr) | Antagonistes des recepteurs du cgrp | |
CY1105607T1 (el) | Η χρηση ενος η1 ανταγωνιστη και ριμεξαολης ως ενα ασφαλες στεροειδες για την θεραπεια ρινιτιδας | |
WO2005016883A3 (fr) | Derives d'acrylamide servant d'antagonistes de l'integrine vla-1, et leurs utilisations | |
WO2005066337A3 (fr) | Composes, compositions pharmaceutiques et procedes therapeutiques pour prevenir et traiter des maladies et des troubles associes a la formation de fibrilles amyloides | |
NO20034232D0 (no) | Anvendelse av glukokortikoid-reseptor-spesifikke antagonister ved behandling av stresslidelser | |
ZA200510170B (en) | Method of reducing the harmful effects of orally or transdermally delivered nicotine | |
AU2001225664A1 (en) | 5-ht3 receptor antagonists for treatment of disorders involving airway constriction | |
WO2006074265A3 (fr) | Therapie combinee et compositions pharmaceutiques utilisees dans le traitement des troubles inflammatoires | |
NO20055098D0 (no) | Anvendelse av 10-hydroksy-10,11-dihydrokarbamazepinderivater for behandling av affektive forstyrrelser | |
WO2002072093A3 (fr) | Utilisation d'antagonistes doubles h3 et m2 dans le traitement de troubles cognitifs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
122 | Ep: pct application non-entry in european phase |